Drug Profile
Ancrod - Nordmark Arzneimittel
Alternative Names: NM-V; ViprinexLatest Information Update: 14 Sep 2020
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; Neurobiological Technologies; Nordmark Arzneimittel
- Class Antithrombotics; Serine endopeptidases; Venoms
- Mechanism of Action Fibrinogen inhibitors; Plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Sensorineural hearing loss
- Market Withdrawal Heparin-induced thrombocytopenia and thrombosis syndrome; Peripheral vascular disorders; Thromboembolism
- Discontinued Stroke
Most Recent Events
- 14 Sep 2020 No development reported - Phase-I/II for Sensorineural hearing loss in Germany, Czech Republic (SC)
- 30 Oct 2018 Nordmark Arzneimittel completes a phase I/II trial in Sensorineural hearing loss in Czech Republic, Germany (SC) (IV) (NCT01621256)
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie